Nueclear Web Banner
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

 
ORIGINAL ARTICLE
Ahead of print publication  

Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy


1 Department of Urology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China
2 Department of Urology, Clinical College, No. 307 Hospital of PLA, Anhui Medical University, Beijing 100071, China
3 Department of Hematopoietic Stem Cell Transplantation, Affiliated Hospital of Academy of Military Medical Sciences; Cell and Gene Therapy, Academy of Military Medical Sciences, Beijing 100071, China
4 Department of Medical Molecular Biology, Beijing Institute of Biotechnology, 27 Tai-Ping Lu Rd, Beijing 100850, China
5 Department of Urology, Affiliated Hospital of Academy of Military Medical Sciences; Department of Urology, Clinical College, No. 307 Hospital of PLA, Anhui Medical University, Beijing 100071, China

Correspondence Address:
Li-Jun Chen,
Department of Urology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None

 > Abstract 


Objective: Sunitinib/sorafenib (SU/SO), dendritic cells (DCs), or DC-cytokine-induced killer (CIK) could significantly prolong progression-free survival (PFS), 3-year overall survival (OS), or 5-year OS for patients with metastatic renal cell carcinoma (mRCC). We retrospectively analyzed the clinical efficacy between SU/SO combined with DC-CIK and SU/SO monotherapy in treating renal cell carcinoma (RCC) patients with metastasis after radical nephrectomy.
Materials and Methods: All patients (n = 34) with postoperative mRCC in our hospital from January 2009 to January 2014 were received either SU/SO monotherapy (Group 1, n = 15) or in combination with DC-CIK (Group 2, n = 19). A retrospective study was based on the primary endpoint (PFS) and secondary endpoint (OS).
Results: At a median follow-up of 19.5 months, in Group 2, as compared with in Group 1, the median PFS was significantly longer (28.0 vs. 11.0 months, P = 0.03). Moreover, the 3-year OS was higher (57.1% vs. 28.6%). The cases of progressive diseases (PDs) and deaths were less in Group 2 than that in Group 1 (PD: 8 vs. 9, deaths: 3 vs. 5); however, the cases of stable diseases were more (11 vs. 6). In addition, the 3-year OS was higher in SU + DC-CIK group than that in SO + DC-CIK group (63.36% vs. 50%). There was no significant difference for PFS between SO + DC-CIK group and SU single agent group.
Conclusions: SU/SO with DC-CIK could significantly prolong the median PFS, improve the 3-year OS rate, prolong the 3-year OS. It is likely to be a new approach for mRCC after radical nephrectomy.

Keywords: 3-year overall survival, dendritic cells-cytokine-induced killer, metastatic renal cell carcinoma, progression-free survival, radical nephrectomy, sorafenib, sunitinib



How to cite this URL:
Mai HX, Mei GH, Zhao FL, Li BT, Tang YY, Zhang B, Xu XJ, Chen LJ. Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy. J Can Res Ther [Epub ahead of print] [cited 2017 Nov 18]. Available from: http://www.cancerjournal.net/preprintarticle.asp?id=180609

.




 

 
Top
 
 
  Search
 
     Search Pubmed for
 
    -  Mai HX
    -  Mei GH
    -  Zhao FL
    -  Li BT
    -  Tang YY
    -  Zhang B
    -  Xu XJ
    -  Chen LJ
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  >Abstract
  In this article

 Article Access Statistics
    Viewed736    
    PDF Downloaded21    

Recommend this journal